At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 17, 2026 at 16:31 ET
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two Class II directors, ratifying the appointment of CBIZ CPAs P.C. as auditors, increasing the number of shares available under its equity incentive plan by 3 million, and increasing its authorized common stock from 150 million to 200 million shares. The filing is a routine proxy statement with no material financial data disclosed.
- Relmada Therapeutics is holding its 2026 annual meeting
- Shareholders will vote to elect two Class II directors: Charles J. Casamento and Sergio Traversa
- Proposal to ratify CBIZ CPAs P.C. as independent auditors for 2026
- Proposal to increase shares available under the 2021 Equity Incentive Plan by 3 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access